National Health Partners, Inc. (NHPR.OB) sell their CARExpress membership programs directly and indirectly through a variety of marketing and distribution partners. The company's programs typically range in price from $9.95 to $39.95 per month, depending upon the program selected. They also offer features to encourage potential members to try out our CARExpress membership programs, including refund guarantees and “trial” periods of free or discounted membership. Healthcare products and services are bundled, priced and marketed utilizing relationship marketing strategies to target the profiled needs of our customers. The discounted prices paid by their members typically range from 20% to 50% off providers’ usual and customary fees. These discounts are designed to save the individual substantially more than the cost of the program itself.

NHPR has achieved positive earnings for the quarter ended September 30, 2010. Revenues for the 3rd quarter grew 12.3% over the same period last year. The Company attributes the net earnings to the significant cost-cutting initiatives taken over the past couple of quarters and which is continuing in the 4th quarter.

“I am thrilled to announce that we have finally achieved profitability,” stated David M. Daniels, President and Chief Executive Officer of National Health Partners. “Due to the fact that our limited medical provider unexpectedly decided to exit the marketplace, we were unable to add any new CARExpress Plus limited medical sales during the 3rd quarter. Yet, despite this temporary setback, we were still able to substantially increase our revenue and reach profitability which is a testament to the underlying strength we have with our core CARExpress health discount programs. Although we achieved positive results in revenues and earnings, we anticipate much better results going forward into 2011.”

National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.” CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company’s primary target customer group is the 47 million Americans who have no health insurance of any kind. The company’s secondary target customer group includes the millions of Americans who lack complete health insurance coverage. The company is headquartered in Horsham, Pennsylvania.

For more information about this company please visit http://www.nationalhealthpartners.com

****

CDC Software Corporation (NASDAQ:CDCS) a global provider of hybrid enterprise software applications and services, announced that, based on current financial projections and estimates, the Company expects its fourth quarter 2010 application sales to be approximately $14.6 million, an increase of approximately 22 percent compared to $12.0 million in the fourth quarter of 2009. Application sales is comprised of license revenue plus Secured Total Contract Value (STCV) for Software-as-a-Service (SaaS) sales secured during the fourth quarter of 2010.

CDC Software Corporation provides a suite of scalable enterprise software applications that delivers industry-specific functionalities worldwide.

****

Crown Equity Holdings Inc. (CRWE.OB) launched its French website crwenewswire.fr , German website crwenewswire.de , and is launching its Canadian website crwenewswire.ca shortly. In addition, Crown Equity Holdings Inc. is in the process of developing its Arabic language CRWENewswire site for news occurring in Pakistan and elsewhere around the world.

“As always, I am thrilled to increase our team of correspondents to offer our readerships a global perspective on top stories. “Not only do our financial results show strong growth during this year but our continued investment in infrastructure will support our future growth,” commented Kenneth Bosket, President and CEO of Crown Equity Holdings Inc.

Crown Equity Holdings Inc. financial results for the nine month period ending September 30, 2010, totaled $1,073,383 compared to $418,959 during 2009.

Also, CRWE subsidiary company, Crown Tele Services Inc. is moving forward and will regularly begin rolling out its internet based voice and video service IP-PBX solutions.

According to ABI Research, the latest global business VoIP services forecasts show that the value of the overall market, which includes VoIP integrated access, SIP trunking, hosted IP-PBX/IP Centrex and managed IP-PBX services, is set to double over the next five years, to exceed $20 billion by 2015.

Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing and Web sites, which bring together targeted audiences and advertisers that want to reach them. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

For more information about Crown Tele Services Inc. please visit http://www.crownteleservices.com

For more information about Crown Equity Holdings Inc. please visit http://www.crownequityholdings.com

****

Complete Genomics, Inc. (NASDAQ:GNOM) a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform, announced that its Chairman, President and CEO Dr. Clifford Reid will present at Xconomy's Computing in the Age of the $1,000 Genome. The event will be held at the Swedish Medical Center in Seattle, WA on Feb. 7. Dr. Reid will discuss new innovations in complete genome sequencing and how the technology will shape the future of genomics medicine.

Complete Genomics, Inc., a life sciences company, develops and commercializes a DNA sequencing platform for human genome sequencing and analysis.

****

Omeros Corporation (NASDAQ:OMER) announced that the European Medicines Agency (EMA) has confirmed that OMS103HP is eligible to be submitted for marketing approval in the European Union (EU) through the EMA centralized procedure. OMS103HP is Omeros' lead product candidate currently in a Phase 3 clinical program evaluating the drug's safety and ability to improve postoperative joint function and reduce pain following anterior cruciate ligament (ACL) reconstruction surgery. Omeros continues to expect the release of Phase 3 results this quarter.

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products focused on inflammation and disorders of the central nervous system.

CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and anticipates receiving 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (NHPR.OB).

CRWEcrweselect0207
NHPRcrweselect0207